SANTA BARBARA, Calif–QAD Inc. (NASDAQ:QADI), a leading provider of enterprise software and services for global manufacturers, today announced the launch of its New York City Life Sciences Forum at the Grand Havana Room on October 7, to provide a forum for Life Sciences manufacturers to learn how to navigate and adapt to impending healthcare industry changes, while building market strength through technology adoption.
By 2015, Life Sciences manufacturers and distributors will be expected to comply with California’s ePedigree Law, mandating mass serialization on the smallest saleable unit-level. To prepare Life Sciences manufacturers, QAD and its panel of experts from Excellis Consulting Corporation, United Drug PLC, and J.P. Morgan Chase, will lead an invitation-only audience through a series of presentations and open discussion on the impending changes to serialization, ePedigree and healthcare reform, and how to leverage technology to transform these challenges into market opportunities.
Greg Cathcart, CEO at Excellis, and Rick Seibert, vice president of Business Development at United Drug PLC, will provide a keynote presentation on the evolving global regulatory landscape surrounding serialization and ePedigree.
“Many biotech and pharmaceutical companies are already moving aggressively to serialize their key products,” noted Riya Cao, director for Life Sciences at QAD. “These manufacturers recognize how serialization provides tractability and accountability in the global supply chain, mitigates risk and counterfeits, protects revenue and builds brand trust.”
A representative of Informatics at Forest Laboratories will present to the forum on the challenges Life Sciences companies face with the new Health Care Reform bill.
Completing the session, John DiFucci, managing director at J.P. Morgan Chase, will show how Life Sciences companies can meet regulatory requirements while driving down costs leveraging QAD Enterprise Applications On Demand.
About the NYC Life Sciences Forum Presenters
Greg Cathcart, CEO at Excellis Consulting Corporation, has more than 25 years in the Life Sciences industry. He currently leads the Excellis team in support of its clients in the areas such as supply chain strategy and execution, and is the sponsor of the www.globaltrackandtrace.org consortium, an industry run consortium focused on the global serialization needs of the industry.
Rick Seibert, vice president of Business Development at United Drug Plc, boasts more than 25 years’ experience in the medical device, surgical instrument and pharmaceutical packaging and services industries. He is an expert in strategic planning, marketing/business development, project management, business process improvement and product development, and holds multiple undergraduate and graduate degrees and certifications.
John DiFucci, managing director at J.P. Morgan, is a software industry veteran. He is an expert in the infrastructure software industry, including the integration, application development, systems and performance management, business intelligence, security, and storage. He holds multiple degrees and licenses.
QAD is a leading provider of enterprise applications for global manufacturing companies specializing in automotive, consumer products, electronics, food and beverage, industrial and life science products. QAD applications provide critical functionality for managing manufacturing resources and operations within and beyond the enterprise, enabling global manufacturers to collaborate with their customers, suppliers and partners to make and deliver the right product, at the right cost and at the right time. For more information about QAD, telephone +1 805-566-6000, or visit the QAD web site at www.qad.com.
Note to Investors: This press release contains certain forward-looking statements made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company’s software products and products that operate with the company’s products; the company’s ability to sustain license and service demand; the company’s ability to leverage changes in technology; the company’s ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company’s products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter’s results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company’s Annual Report on Form 10-K for fiscal 2009 ended January 31, 2009.